Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

Hemochromatosis Clinical Trial

Official title:

Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00349453
• Other study ID #: DF-2/CH
• Status: Completed
• Phase: Phase 2
• First received: July 6, 2006
• Last updated: December 9, 2011
• Start date: March 2005
• Est. completion date: May 2011

Study information

• Verified date: December 2011
• Source: Lipomed
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine

Description:

Patients with refractory anemias requiring regular blood transfusions accumulate iron at the rate of approximately 0.5 mg/kg/day, which may lead to serious organ toxicity, e.g. to the heart, liver and endocrine organs. The human body has no active mechanism for the excretion of excess iron. Therefore multiply transfused patients will develop a secondary hemosiderosis, if excess iron is not excreted by a chelating agent. Symptoms of iron-overload occur when body iron stores reach 10-20 g. At higher levels severe, even fatal complications, particularly cardiac failure, may develop.

Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug, but is expensive and must be given by slow subcutaneous or intravenous infusion for 8-12 hours a day during 5-7 days weekly at a dosage of 40-50 mg/kg body weight/day. This often leads to failure of compliance of the patient and therefore to inefficient iron chelation. Further, some patients are hypersensitive to desferrioxamine and others suffer from toxicity, e.g. to the ears or eyes.

Deferiprone (L1; CP20; 1,2 dimethyl-3-hydroxypyrid-4-one) is an orally active iron chelator investigated in various clinical trials since 1987. Dosages of 75 - 100 mg/kg body weight/day of L1 have been considered effective to maintain stable iron balance (urinary iron excretion of 0.5 mg/kg/day) and to reduce serum ferritin levels between 6% and 25% within one year of treatment in iron-overloaded thalassemic patients. There exists long-term experience with patients who have received deferiprone continuously for more than 10 years so far. The main side effects encountered during a deferiprone therapy are arthropathy, gastrointestinal symptoms, headache, and mild zinc deficiency. These adverse reactions are usually reversed on reducing the dose or discontinuing the drug. Except for severe joint symptoms in few patients, most of the subjects in different clinical trials have been able to continue with L1 therapy for a long term. The most severe, but rare complication following administration of deferiprone is agranulocytosis or neutropenia.

A new treatment regimen combining deferiprone with desferrioxamine is currently being investigated in many countries. Preliminary data have demonstrated that the combined use of both drugs is highly active showing an additive or even synergistic effect (significant decrease of serum ferritin and hepatic iron content, increase of urinary iron excretion). This synergism could be explained by the different mode of action of the two drugs. It could be demonstrated that patients who were not sufficiently chelated with desferrioxamine or deferiprone, could achieve a negative iron balance with the combination treatment of both drugs. The combined regimen was generally well tolerated. It has been speculated that the individual toxicity profile of both drugs can be positively influenced by the simultaneous administration of L1 and DFO. The daily treatment with L1 tablets combined with at least twice a week administration of parenteral desferrioxamine is more patient-convenient and therefore may enhance the patient's compliance.

The primary aim of this study is to systematically investigate the long-term safety (toxicity assessment according to CTCAE v3.0) of deferiprone either given alone or in combination with desferrioxamine. Further, in patients agreeing to perform annual SQUID analysis of the liver, the annual change of liver iron concentration (LIC) will be examined for four years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 4 Years and older

Eligibility

Inclusion Criteria:

• Iron overloaded male or female patients with primary or secondary hemochromatosis

• Age: 4 years and older

• Patients with desferrioxamine toxicity or allergy (e.g. visual or hearing defects, bone abnormalities, reactions at injection site)

• Patients unable or unwilling to comply satisfactorily with regular desferrioxamine administration on 5-7 days/week

• Combination treatment: patients not sufficiently chelated with desferrioxamine or deferiprone monotherapy

• Patients must be willing to undergo routine screening including medical history, physical examination and hematology, biochemistry and other laboratory tests

• Written informed consent

Exclusion Criteria:

• Children under 4 years of age

• Female and male of reproductive age, sexually active but not taking adequate contraceptive precaution

• Woman who are pregnant or breast-feeding

• Patients with HIV

• Patients with active hepatitis requiring treatment

• Patients with severe hepatic failure, cirrhosis

• Patients with neutropenia (neutrophils less than 1.5 exp9/l, MDS: less than 0.5 exp9/l)

• Patients with thrombocytopenia (platelets less than 100 exp9/l, MDS: less than 20 exp9/l)

• Patients with decompensated heart failure (LVEF less than 40% or patients under continuous cardiac medication)

• Patients with severe renal failure

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hemochromatosis

Intervention

Drug:
• Deferiprone (L1)
50-100 mg/kg body weight daily
• Deferiprone (L1)
75 mg/kg body weight daily
• Desferrioxamine
35-50 mg/kg body weight on 2 or more days per week

Locations

Country	Name	City	State
Switzerland	Cantonal Hospital	Aarau	Aargau
Switzerland	Cantonal Hospital, Children's Clinic	Aarau	Aargau
Switzerland	Private practice	Arzo	Ticino
Switzerland	Private children's practice	Bern
Switzerland	Private children's practice	Brig	Wallis
Switzerland	Cantonal Hospital Graubünden	Chur	Graubünden
Switzerland	Private practice	Lugano	Ticino
Switzerland	Regional Hospital	Lugano	Ticino
Switzerland	Private practice	Oerlikon	Zurich
Switzerland	Private practice	Riva San Vitale	Ticino
Switzerland	Children's Hospital of Eastern Switzerland	St. Gallen
Switzerland	University Children's Hospital	Zurich
Switzerland	University Hospital	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Lipomed

Country where clinical trial is conducted

Switzerland, 

References & Publications (2)

Töndury P, Kontoghiorghes GJ, Ridolfi-Lüthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol. 1990 Dec;76(4):550-3. — View Citation

Töndury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol. 1998 Jun;101(3):413-5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Liver Iron Concentration (LIC) by SQUID		Yearly	No
Primary	Long-term safety profile		Long-term	Yes
Secondary	Serum ferritin		At quarterly control visits	No
Secondary	Urinary Iron Excretion (UIE)		At six-monthly control visits	No
Secondary	Heart iron content (optional) by MRI T2* and MRI SIR		Yearly	No